Enlivex Therapeutics (NASDAQ:ENLV) Rating Lowered to “Sell” at Wall Street Zen

Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

ENLV has been the topic of a number of other research reports. D. Boral Capital reissued a “hold” rating on shares of Enlivex Therapeutics in a report on Monday, November 24th. HC Wainwright lifted their price target on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $13.00.

Enlivex Therapeutics Price Performance

ENLV stock opened at $1.11 on Friday. Enlivex Therapeutics has a 1 year low of $0.66 and a 1 year high of $2.10. The company has a market cap of $263.49 million, a P/E ratio of -2.02 and a beta of 1.62. The stock’s fifty day moving average price is $0.95 and its 200-day moving average price is $1.05.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. As a group, analysts expect that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Institutional Investors Weigh In On Enlivex Therapeutics

A number of institutional investors have recently bought and sold shares of the business. HRT Financial LP lifted its position in shares of Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after acquiring an additional 135,198 shares in the last quarter. Renaissance Technologies LLC raised its stake in Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after purchasing an additional 156,336 shares during the period. Jane Street Group LLC lifted its holdings in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares in the last quarter. Susquehanna International Group LLP purchased a new position in Enlivex Therapeutics in the 3rd quarter worth approximately $57,000. Finally, Citizens Financial Group Inc. RI bought a new position in Enlivex Therapeutics in the 3rd quarter worth approximately $241,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.